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Abstract We reviewed and categorized 638 of 809
patients who were registered in the Japan Adult Leukemia
Study Group acute myeloid leukemia (AML)-97 protocol
using morphological means. Patients with the M3 subtype
were excluded from the study group. According to the
WHO classiﬁcation, 171 patients (26.8%) had AML with
recurrent genetic abnormalities, 133 (20.8%) had AML
with multilineage dysplasia (MLD), 331 (51.9%) had AML
not otherwise categorized, and 3 (0.5%) had acute leuke-
mia of ambiguous lineage. The platelet count was higher
and the rate of myeloperoxidase (MPO)-positive blasts was
lower in AML with MLD than in the other WHO catego-
ries. The outcome was signiﬁcantly better in patients with
high (C50%) than with low (\50%) ratios of MPO-positive
blasts (P\0.01). The 5-year survival rates for patients
with favorable, intermediate, and adverse karyotypes were
63.4, 39.1, and 0.0%, respectively, and 35.5% for those
with 11q23 abnormalities (P\0.0001). Overall survival
(OS) did not signiﬁcantly differ between nine patients with
t(9;11) and 23 with other 11q23 abnormalities (P = 0.22).
Our results conﬁrmed that the cytogenetic proﬁle, MLD
phenotype, and MPO-positivity of blasts are associated
with survival in patients with AML, and showed that each
category had the characteristics of the WHO classiﬁcation
such as incidence, clinical features, and OS.
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1 Introduction
The French-American-British (FAB) classiﬁcation of acute
myeloid leukemia (AML), based on morphological and
cytochemical ﬁndings, was established in 1976 and has
since become the standard classiﬁcation [1, 2]. However,
speciﬁc chromosomal and genetic abnormalities that have
been extracted from analyses of prognostic factors for
AML are recognized as important in selecting treatment
strategies and are reﬂected in the AML classiﬁcation as
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The 1999 World Health Organization (WHO) classiﬁcation
includes morphological, immunological, cytogenetic,
genetic, and clinical features [4–6]. The WHO and FAB
classiﬁcations differ in several aspects. The blast threshold
required for a diagnosis of AML was reduced from 30 to
20%, and new AML categories have been added for
cytogenetic abnormalities, the presence of multilineage
dysplasia (MLD), as well as a history of chemotherapy and
subtypes for acute basophilic leukemia, acute panmyelosis
with myeloﬁbrosis, and myeloid sarcoma. The WHO
classiﬁcation comprises more subtypes and is more com-
prehensive than the FAB classiﬁcation.
Cytogenetic features are important prognostic factors in
AML [3, 7–12]. However, 11q23 abnormalities have not yet
been established as a cytogenetic risk classiﬁcation. Over 30
partner genes with 11q23 abnormalities have been descri-
bed, and some reports indicate that patients with t(9;11)
have a relatively more favorable prognosis than those with
other partner chromosomes/partner genes [13–16].
In the present study, we reviewed stained smears of
blood and bone marrow from patients who were registered
in the Japan Adult Leukemia Study Group (JALSG) AML-
97 trial, and classiﬁed them into FAB subtypes and WHO
categories. We also evaluated their survival on the basis of
the WHO classiﬁcation, the myeloperoxidase (MPO)-pos-
itivity of blasts, and cytogenetic ﬁndings including 11q23
abnormalities.
2 Patients and methods
2.1 Patients
Between December 1997 and July 2001, 809 patients aged
from 15 to 66 years with untreated AML (excluding M3)
were registered from 103 institutions in the AML-97 trial
of the JALSG. The patients were diagnosed with AML
according to the FAB criteria at each institution. Patients
with a history of MDS, hematological abnormalities before
the diagnosis of AML, or a history of chemotherapy were
not eligible for the AML-97 trial.
2.2 Treatment strategies
Details of the JALSG AML-97 treatment protocol are
described elsewhere [17]. In brief, all patients underwent
induction therapy consisting of idarubicin (3 days) and Ara-
C (7 days). Patients who achieved complete remission were
randomized into one of two arms of consolidation chemo-
therapy alone or in combination with maintenance
chemotherapy. Patients who were placed into intermediate/
poorriskgroupsaccordingtotheJALSGscoringsystem[17]
and who had an HLA-identical sibling (B50 years old) were
simultaneouslyassignedtoreceiveallogeneichematopoietic
stem cell transplantation during their ﬁrst remission.
2.3 Morphologic and cytochemical analyses
Peripheral blood and bone marrow smears from registered
patients were sent to Nagasaki University for staining with
May-Giemsa, MPO, and esterase, and the diagnosis was
then reevaluated by the Central Review Committee for
Morphological Diagnosis. Patients were subsequently cat-
egorized according to the FAB and WHO classiﬁcations.
Dyserythropoietic features were deﬁned as [50% dys-
plastic features in at least 25 erythroblasts and
dysgranulopoietic features including C3 neutrophils with
hyposegmented nuclei (pseudo-Pelger–Heut anomaly), and
hypogranular or agranular neutrophils ([50% of C10
neutrophils). Dysmegakaryopoietic features were deﬁned
as C3 megakaryocytes that were micronuclear, multisepa-
rate nuclear, or large mononuclear [18].
We assessed the ratios (%) of MPO-positive blasts on
MPO-stained bone marrow smears using the diamino-
benzidine method [19].
2.4 Cytogenetic analysis
Cytogenetic analysis was performed at either laboratories
in participating hospitals or authorized commercial labo-
ratories. The karyotypes of leukemic cells were collected
through the JALSG AML-97 case report forms and
reviewed by the Central Review Committee for Karyo-
typing. The patients were classiﬁed into favorable,
intermediate, or adverse risk groups based on karyotypes
according to results of the Medical Research Council
(MRC) AML 10 trial [3]. The favorable risk group inclu-
ded patients with t(8;21) and inv(16), whether alone or in
combination with other abnormalities. The intermediate
risk group included those with a normal karyotype and
other abnormalities that were not classiﬁed as either
favorable or adverse. The adverse risk group included
patients with a complex karyotype with four or more
numerical or structural aberrations, -5, deletion (5q), and
-7, whether alone or in combination with intermediate risk
or other adverse risk abnormalities.
2.5 Statistical analysis
The overall survival (OS) for all patients was deﬁned as the
interval from the date of diagnosis to that of death. We
applied the Kaplan–Meier method to estimate OS and
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1235-year survival. We compared survival rates between
groups using the log-rank test (Stat View J 5.0). Differ-
ences were examined by the Chi-square test using Excel
software. All P-values are two-sided, and values \0.05
were considered signiﬁcant.
3 Results
3.1 Patient characteristics
Of the 809 registered patients, 638 were consistent with the
WHO classiﬁcation. Data were incomplete for 10 of the
638 patients. Table 1 lists the characteristics of the
patients. The median age of all 638 patients (390 males and
248 females) was 45 years (range 15–66 years). The
median values of WBC, hemoglobin (Hb), platelets, and
the ratio of blasts in the bone marrow were 13.7 9 10
9/l,
8.3 g/dl, 52.0 9 10
9/l, and 56.0%, respectively.
3.2 FAB classiﬁcation
Table 2 shows the FAB classiﬁcation of the 638 patients.
Most were classiﬁed as M2 (n = 261; 40.9%), followed by
M4 (n = 148; 23.2%), and M1 (n = 109; 17.1%) with M0,
M4Eo, M5a, M5b, M6, M7, and acute leukemia of
ambiguous lineage comprising the remainder in that order.
3.3 WHO classiﬁcation and clinical characteristics
Table 3 shows the patients categorized according to the
WHO classiﬁcation. The ﬁrst category of AML with
recurrent genetic abnormalities accounted for 171 patients
(26.8%), 133 (20.8%) were in the second category of AML
with MLD, 331 (51.9%) were in the fourth category of
AML not otherwise categorized, and 3 (0.5%) were cate-
gorized as having acute leukemia of ambiguous lineage.
Most patients in the second category were identical to those
with a de novo MLD phenotype. We found that 144 patients
diagnosed with the MLD phenotype comprised 133 (92.4%)
in the second category, 10 (7.0%) with 11q23 abnormalities,
and 1 (0.7%) with acute leukemia of ambiguous lineage.
Figure 1 shows the OS of each category. The 5-year sur-
vival rates of the ﬁrst, second, and fourth categories were
58.2, 22.5, and 40.9% (P\0.0001), respectively.
Table 1 Patient characteristics
Age (year) 45 (15–66)
Male/female 390/248
WBC count (910
9/l) 13.7 (0.4–709)
Hemoglobin (g/dl) 8.3 (3.8–17.2)
Platelet count (910
9/l) 52 (0–890)
Bone marrow blasts (%) 56 (6–99)
Values are presented as the median (range)
WBC white blood cell
Table 2 Number of patients according to the FAB classiﬁcation
Subtype Description No. of
patients
%
M0 Minimally differentiated acute myeloid
leukemia (AML)
30 4.7
M1 AML without maturation 109 17.1
M2 AML with maturation 261 40.9
M4 Acute myelomonocytic leukemia
(AMMoL)
148 23.2
M4Eo AMMoL with eosinophils 23 3.6
M5a Acute monoblastic leukemia 19 3.0
M5b Acute monocytic leukemia 24 3.8
M6 Acute erythroleukemia 16 2.5
M7 Acute megakaryoblastic leukemia 5 0.8
Acute leukemia of ambiguous lineage 3 0.5
Total 638 100
Table 3 Number of patients according to the WHO classiﬁcation
Category and subtype No. of
patients
%
I. AML with recurrent genetic abnormalities 171 26.8
t(8;21)(q22;q22);(AML1/ETO) 113 17.7
inv(16)(p13;q22) or t(16;16)(p13;q22);(CBFb/
MYH11)
26 4.1
t(15;17)(q22;q12)(PML/RARa)– –
11q23(MLL)abnormalities 32 5.0
II. AML with multilineage dysplasia 133 20.8
Following MDS – –
Without antecedent MDS 133 20.8
III. AML and MDS, therapy-related – –
Alkylating agent-related – –
Topoisomerase type II inhibitor-related – –
Other types – –
IV. AML not otherwise categorized 331 51.9
AML, minimally differentiated 25 3.9
AML without maturation 99 15.5
AML with maturation 108 16.9
Acute myelomonocytic leukemia (AMMoL) 63 9.9
AMMoL with eosinophilia 5 0.8
Acute monoblastic leukemia 8 1.3
Acute monocytic leukemia 16 2.5
Acute erythroid leukemia 6 0.9
Acute megakaryoblastic leukemia 1 0.2
Acute leukemia of ambiguous lineage 3 0.5
Total 638 100
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123Table 4 compares the clinical features among the WHO
categories. The mean values of platelets, WBC, Hb, and the
ratio (%) of blasts in bone marrow and of MPO-positive
blasts signiﬁcantly differed, whereas age did not signiﬁ-
cantly differ. Patients in the second category had a higher
platelet count (111.0 9 10
9/l), whereas those with 11q23
abnormalities had a lower count (38.3 9 10
9/l) compared
with those of other subtypes.
The WBC count of patients with t(8;21) was 1.4 9 10
9/l
and lower than in other subtypes. The MPO-positive rate of
blasts among patients with t(8;21) was higher (93.3%) and
that of patients in the second category was lower (34.0%),
than in other subtypes. All patients were grouped as high-
or low-MPO according to C50% or\50% of MPO-positive
blasts, respectively. A total of 339 patients (53.1%) were
classiﬁed as high-MPO, 268 (42.0%) as low-MPO, and the
MPO status of blasts could not be assessed in 31 (4.9%).
Figure 2 shows the OS of patients with high- or low-MPO.
The 5-year survival rate for patients with high or low-MPO
was 50.7 and 29.6%, respectively (P\0.0001).
3.4 Cytogenetics
All 638 patients were classiﬁed into favorable (n = 139;
21.8%), intermediate (n = 413; 64.7%), and adverse
(n = 54; 8.5%) cytogenetic risk groups (Table 5). Figure 3
shows the OS according to this stratiﬁcation. The 5-year
survival rates were 63.4, 39.3, and 0.0% in the favorable,
intermediate (except for those with 11q23 abnormalities),
and adverse risk groups, respectively, and 35.5% in the
group with 11q23 abnormalities (P\0.0001).
The numbers of patients with or without MLD and high-
or low-MPO in each cytogenetic risk group are listed in
Table 6. None of those with the MLD phenotype were
classiﬁed into the favorable risk group, while 129 (89.6%)
and 15 (10.4%) of 144 patients with MLD were classiﬁed
into intermediate or adverse risk groups, respectively. Only
15 patients (4.4%) in the high-MPO group were classiﬁed
as having an adverse risk, while 11 (4.1%) in the low-MPO
group were included in the favorable risk group.
The 32 patients with 11q23 abnormalities comprised 11
(34.4%) with t(11;19), 9 (28.1%) with t(9;11), 5 (15.6%)
with del(11)(q23), 4 (12.5%) with t(6;11), and 3 (9.4%)
with t(11;17). Figure 4 shows the OS of the intermediate
risk group. The 5-year survival rate was 44.0% in patients
with a normal karyotype, 35.5% in those with 11q23
abnormalities, and 30.6% in other patients including those
with t(7;11), t(6;9), and Ph(+) abnormalities, respectively
(P = 0.033).
Table 7 shows the relationship between t(9;11) (n = 9)
and other 11q23 abnormalities (n = 23). More patients
with low-MPO, without MLD, or with the FAB M5 sub-
type were found in the group with t(9;11) than with other
11q23 abnormalities. The survival rates between the two
groups did not signiﬁcantly differ (P = 0.22, data not
shown).
4 Discussion
We attempted to classify selected patients who were
reviewed morphologically and had available chromosomal
data according to the WHO system. However, our series
had some limitations in terms of analysis and patient
selection. Although we obtained chromosomal data,
genetic data were not available. Patients who were diag-
nosed with AML M3 or who had t(15;17), a history of
MDS, or preceding hematological abnormalities, or who
had previously undergone chemotherapy, were not eligible
for the present study. However, multicenter trials might
have some advantages in diagnosing AML according to the
WHO classiﬁcation, because morphological diagnoses and
karyotypes are reviewed by the corresponding institutional
committees.
The incidence of each category of the WHO classiﬁca-
tion was similar to those in several reports when patients
with t(15;17) and therapy-related AML were excluded [20–
22]. We and several others have shown that approximately
30% of patients have recurrent genetic abnormalities.
Multiplex reverse transcriptase-polymerase chain reaction
(RT-PCR) assays have recently been applied to analyze
cytogenetic abnormalities [21, 23, 24]. This method might
cause the frequency of the ﬁrst WHO category to increase.
Thus, the multiplex RT-PCR assay might have to be
incorporated into the WHO system. The JALSG has started
a cohort study in which all AML patients in participating
hospitals are registered and analyzed according to the
WHO classiﬁcation. That study should clarify the real
ratios of the AML subtypes in the WHO classiﬁcation.
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123Few reports have included clinical data with the WHO
classiﬁcation. We found that the platelet count was higher
among patients in the second category than in other cate-
gories. This supports our previous ﬁnding that the platelet
count is higher in patients with AML accompanied by the
MLD phenotype [25]. Among patients with MLD, none
were in the favorable risk group, whereas the intermediate
or adverse risk ratios among these patients were 89.6 and
10.4%, respectively. These differences might inﬂuence the
ﬁnding that OS was better among patients without than
with MLD (P = 0.0002, data not shown). Previous studies
have also associated the MLD phenotype with a poorer
outcome, although MLD is not signiﬁcantly prognostic on
multivariate analysis [18, 26], and a German group showed
that dysplastic features correlate with adverse karyotypes
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Fig. 2 Overall survival of patients with high or low MPO-positive
blasts
Table 5 Distribution of patients classiﬁed by cytogenetic risk
Cytogenetic risk group No. of patients %
Favorable 139 21.8
t(8;21) 113 17.7
inv(16) 26 4.1
Intermediate 413 64.7
Normal karyotype 267 41.8
11q23 32 5.0
Ph(+) 7 1.1
t(7;11)(p15;p15) 4 0.6
t(6;9) 4 0.6
Other 131 20.5
Adverse 54 8.5
Complex 41 6.4
-7 2 0.3
abn3 5 0.8
del5q 2 0.3
-5 1 0.2
Other 3 0.5
Total 638 100.0
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123[26]. Furthermore, patients in the second category had a
lower MPO-positive rate of blasts, whereas those with
t(8;21) had a higher rate. Patients with high- and low-MPO
were more frequently observed in the favorable and
adverse risk groups, respectively. Multivariate analysis has
shown that MPO is a signiﬁcant factor affecting OS [19].
We did not assess prognostic factors by multivariate
analysis here because the main theme of this study was to
categorize patients according to the WHO classiﬁcation,
and we have already examined these in a previous series
[18, 19].
Several studies have demonstrated the impact of speciﬁc
cytogenetic abnormalities on survival in AML [3, 7–12,
20–22]. The cytogenetic risk groups stratiﬁed the AML
patients in the present study according to the MRC system,
as in these reports [3]. Therefore, we conﬁrmed the clinical
usefulness of cytogenetics as the ﬁrst category of the WHO
classiﬁcation. We found that 32 patients had 11q23
abnormalities. The MRC system revealed that de novo and
secondary AML patients with 11q23 abnormalities had an
intermediate outcome with an OS rate of 45% at 5 years
(n = 60; median age, 17 years) in a younger cohort [3] and
an OS rate of 0% at 5 years (n = 11; median age 64 years)
in an elderly cohort [7]. In contrast, SWOG/ECOG trials
including adult de novo AML patients (age, 16–55 years)
assigned those with 11q abnormalities to the unfavorable
cytogenetic subgroup [8]. Our data showed that patients
with 11q23 abnormalities have an intermediate rather than
adverse outcome. The prognostic effect of 11q23 abnor-
malities might depend on the partner gene. Several studies
have shown that 11q23 abnormalities with t(6;11) and
t(10;11) are associated with a poor prognosis, whereas
t(9;11) is associated with a superior OS and such patients
might respond well to intensive treatment, especially when
the chemotherapy regimen includes high-dose cytarabine
[15, 27–30]. The CALGB study has shown that the median
OS of 13.2 months among 23 patients with t(9;11) was
signiﬁcantly longer than the 7.7 months among 24 patients
with other 11q23 rearrangements (P = 0.009) [30]. In a
recent CALGB series of 54 patients with 11q23 abnor-
malities, 27 patients with t(9;11) had an intermediate
outcome and a median OS of 13.2 months, whereas those
with t(6;11) or t(11;19) had a poor outcome of 7.2 or 8.4
months [15]. Conversely, Schoch et al. showed that 14
patients with t(9;11) had a median OS of 10.0 months
compared with the 12.8 months of 26 patients with other
MLL rearrangements, and that the two cytogenetic groups
did not signiﬁcantly differ [13]. Our data showed that nine
patients with t(9;11) were more frequently involved in M5.
The MPO and MLD features signiﬁcantly differed between
patients with t(9;11) and those with other 11q23 abnor-
malities. However, the CALGB study found no signiﬁcant
differences in myelodysplastic features between the two
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Fig. 3 Overall survival of patients stratiﬁed according to cytogenetic
risk groups. Signiﬁcant differences were observed between patients
with a favorable, intermediate (except 11q23), and adverse karyotype
(P\0.0001)
Table 6 Relationship between cytogenetic risk groups and MLD
phenotype or MPO-positive rates of blasts
Favorable
n = 139
Intermediate
n = 445
Adverse
n = 54
Total
MLD
+ 0 129 (89.5%) 15 (10.4%) 144
- 138 (28.2%) 292 (59.6%) 38 (7.8%) 490
Unknown 1 2 1 4
MPO
High 123 (36.3%) 201 (59.3%) 15 (4.4%) 339
Low 11 (4.1%) 221 (82.5%) 36 (13.4%) 268
Unknown 5 23 3 31
High- and low-MPO indicates a percentage of myeloperoxidase
positive blasts C50 or\50%, respectively
MLD multilineage dysplasia
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 500 1000 1500 2000 2500
) 4 6 2 = n (   e p y t o y r a k   l a m r o N
) 2 3 = n (   3 2 q 1 1
) 3 4 1 = n (   s r e h t O
3 3 0 . 0 = p
Days
P
r
o
b
a
b
i
l
i
t
y
Fig. 4 Overall survival of patients with subtypes of intermediate
cytogenetic risk. Signiﬁcant differences were observed between
patients with a normal karyotype and those with 11q23 abnormalities
(P = 0.033)
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123cytogenetic groups [30]. In terms of OS, our results showed
no signiﬁcant differences between patients with t(9;11) and
those with other 11q23 abnormalities (P = 0.22). Some
problems are associated with the analyses of 11q23
abnormalities. We had few patients with these abnormali-
ties, particularly individual translocations, and genetic
analysis was not performed. Thus, the prognostic risk of
11q23 abnormalities cannot be concluded from the present
study. Nonetheless, these abnormalities were never asso-
ciated with a favorable risk. To classify 11q23
abnormalities into each prognostic risk group, further
investigations and genetic analyses of a large number of
patients with 11q23 abnormalities are required.
The fourth WHO category, which is not otherwise cat-
egorized, accounted for 52% of patients in the present
study. Most of them were classiﬁed into the intermediate
risk group, and no prognostic subdivisions were valuable.
Using cytogenetic features as a prognostic factor in groups
with a normal karyotype has limitations, and such patients
accounted for 64.6% of the intermediate risk group (data
not shown). Additional factors are required to stratify these
patients. We and several others suggested that differences
could be based on molecular genetic analysis [22, 31–35].
For example, FLT3 mutations are important biomarkers of
a normal karyotype and might be valuable for stratifying
the intermediate risk group. Further follow-up studies
might also shed light on the roles of FLT3 ITD mutations
in the development of AML and aid their use as novel
molecular targeting agents against AML [22, 32]. Bienz
et al. identiﬁed CEBPA mutations, FLT3-ITD, and differ-
ing levels of BAALC expression as having independent
prognostic signiﬁcance in patients with a normal karyotype
[33]. If these genetic markers can be conﬁrmed as being of
clinical signiﬁcance, genetic analyses will probably be
incorporated into the WHO classiﬁcation.
In summary, our results conﬁrmed those of previous
studies showing the prognostic signiﬁcance of cytogenet-
ics, MLD, and MPO-positivity of blasts in AML.
Furthermore, we categorized patients with de novo AML
according to the WHO classiﬁcation and showed the clin-
ical characteristics and OS of each category.
Acknowledgments We thank the clinicians and leaders of all the
institutions who entered their patients into the JALSG AML-97 study
and provided the necessary data to make this study possible. This
work was supported in part by a grant from the Ministry of Education,
Culture, Sports, Science and Technology of Japan.
References
1. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the
classiﬁcation of acute leukaemias. French-American-British
(FAB) co-operative group. Br J Haematol. 1976;33:451–8.
2. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised
criteria for the classiﬁcation of acute myeloid leukemia: a report
of the French-American-British Cooperative Group. Ann Intern
Med. 1985;103:620–5.
3. Grimwade D, Walker H, Oliver F, et al. The importance of
diagnostic cytogenetics on outcome in AML: analysis of 1,612
patients entered into the MRC AML 10 trial. Blood.
1998;92:2322–33.
4. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization
classiﬁcation of neoplastic diseases of the hematopoietic and
lymphoid tissues: report of the Clinical Advisory Committee
meeting-Airlie House, Virginia, November 1997. J Clin Oncol.
1999;17:3835–49.
5. Vardiman JW, Harris NL, Brunning RD. The World Health
Organization (WHO) classiﬁcation of the myeloid neoplasms.
Blood. 2002;100:2292–302.
6. Brunning RD, Matutes E, Harris NL, et al. Acute myeloid leu-
kaemias. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds)
Pathology and genetics of tumors of haematopoietic and lym-
phoid tissues. Lyon: IARC Press; 2001. p. 75–107.
7. Grimwade D, Walker H, Harrison G, et al. The predictive value
of hierarchical cytogenetic classiﬁcation in older adults with
acute myeloid leukemia (AML): analysis of 1065 patients entered
into the United Kingdom Medical Research Council AML 11
trial. Blood. 2001;98:1312–20.
8. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis
predicts outcome of preremission and postremission therapy in
adult acute myeloid leukemia: a Southwest Oncology Group/
Eastern Cooperative Oncology Group study. Blood.
2000;96:4075–83.
9. Rowe JM, Liesveld JL. Treatment and prognostic factors in acute
myeloid leukaemia. Baillieres Clin Haematol. 1996;9:87–105.
10. Schoch C, Kern W, Schnittger S, Buchner T, Hiddemann W,
Haferlach T. The inﬂuence of age on prognosis of de novo acute
myeloid leukemia differs according to cytogenetic subgroups.
Haematologica. 2004;89:1082–90.
11. Arber DA, Stein AS, Carter NH, Ikle D, Forman SJ, Slovak ML.
Prognostic impact of acute myeloid leukemia classiﬁcation:
Table 7 Comparison of t(9;11) and other 11q23 abnormalities
No. of patients Auer MPO* MLD* FAB Median age
(year)
Median survival
(day)
+ - High Low + - M1 M2 M4 M4Eo M5a** M5b
t(9;11) 9 0 9 1 8 0 9 0 0 3 0 6 0 39 1031.00
Other 11q23 23 5 18 13 10 10 13 1 3 13 1 2 3 48 520.00
Total 32 5 27 14 18 10 22 1 3 16 1 8 3 44.5 531.5
High- and low-MPO indicates a percentage of myeloperoxidase-positive blasts C50 or\50%, respectively
MLD multilineage dysplasia
* P\0.05, ** P\0.01
150 M. Wakui et al.
123importance of detection of recurring cytogenetic abnormalities
and multilineage dysplasia on survival. Am J Clin Pathol.
2003;119:672–80.
12. Bloomﬁeld CD, Shuma C, Regal L, et al. Long-term survival of
patients with acute myeloid leukemia: a third follow-up of the
Fourth International Workshop on Chromosomes in Leukemia.
Cancer. 1997;80:2191–8.
13. Schoch C, Schnittger S, Klaus M, Kern W, Hiddemann W, Ha-
ferlach T. AML with 11q23/MLL abnormalities as deﬁned by the
WHO classiﬁcation: incidence, partner chromosomes, FAB sub-
type, age distribution, and prognostic impact in an unselected
series of 1897 cytogenetically analyzed AML cases. Blood.
2003;102:2395–402.
14. Dohner K, Tobis K, Ulrich R, et al. Prognostic signiﬁcance of
partial tandem duplications of the MLL gene in adult patients 16
to 60 years old with acute myeloid leukemia and normal cyto-
genetics: a study of the Acute Myeloid Leukemia Study Group
Ulm. J Clin Oncol. 2002;20:3254–61.
15. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic
abnormalities are predictive of induction success, cumulative
incidence of relapse, and overall survival in adult patients with de
novo acute myeloid leukemia: results from Cancer and Leukemia
Group B (CALGB 8461). Blood. 2002;100:4325–36.
16. Mitterbauer-Hohendanner G, Mannhalter C. The biological and
clinical signiﬁcance of MLL abnormalities in haematological
malignancies. Eur J Clin Invest. 2004;34:12–24.
17. Miyawaki S, Sakamaki H, Ohtake S, et al. A randomized, pos-
tremission comparison of four courses of standard-dose
consolidation therapy without maintenance therapy versus three
courses of standard-dose consolidation with maintenance therapy
in adults with acute myeloid leukemia: the Japan Adult Leukemia
Study Group AML97 study. Cancer. 2005;104:2726–34.
18. Miyazaki Y, Kuriyama K, Miyawaki S, et al. Cytogenetic het-
erogeneity of acute myeloid leukemia (AML) with trilineage
dysplasia: Japan Adult Leukemia Study Group-AML 92 study. Br
J Haematol. 2003;120:56–62.
19. Matsuo T, Kuriyama K, Miyazaki Y, et al. The percentage of
myeloperoxidase-positive blast cells is a strong independent
prognostic factor in acute myeloid leukemia, even in the patients
with normal karyotype. Leukemia. 2003;17:1538–43.
20. Arber DA, Stein AS, Carter NH, Ilie D, Forman SJ, Slovak ML.
Prognostic impact of acute myeloid leukemia classiﬁcation. Am J
Clin Pathol. 2003;119:672–80.
21. Yanada M, Suzuki M, Kawashima K, et al. Long-term outcomes
for unselected patients with acute myeloid leukemia categorized
according to the World health Organization classiﬁcation: a sin-
gle-center experience. Eur J Haematol. 2005;74:418–23.
22. Bao L, Wang X, Ryder J, et al. Prospective study of 174 de novo
acute myelogenous leukemias according to the WHO classiﬁca-
tion: subtypes, cytogenetic features and FLT3 mutations. Eur J
Haematol. 2006;77:35–45.
23. Mayer-Monard S, Parlier J, Passweg J, et al. Combination of
broad molecular screening and cytogenetic analysis for genetic
risk assignment and diagnosis in patients with acute leukemia.
Leukemia. 2006;20:247–53.
24. Olesen LH, Clausen N, Dimitrijevic A, Kerndrup G, Kjeldsen E,
Hokland P. Prospective application of a multiplex reverse tran-
scription-polymerase chain reaction assay for the detection of
balanced translocations in leukaemia: a single-laboratory study of
390 paediatric and adult patients. Br J Haematol. 2004;127:59–
66.
25. Kuriyama K, Tomonaga M, Matsuo T, et al. Poor response to
intensive chemotherapy in de novo acute myeloid leukaemia with
trilineage myelodysplasia. Br J Haematol. 1994;86:767–73.
26. Haferlach T, Schoch C, Lofﬂer H, et al. Morphologic dysplasia in
de novo acute myeloid leukemia (AML) is related to unfavorable
cytogenetics but has no independent prognostic relevance under
the conditions of intensive induction therapy: results of a multi-
parameter analysis from the German AML Cooperative Group
studies. J Clin Oncol. 2003;21:256–65.
27. Martineau M, Berger R, Lillington DM, Moorman AV, Secker-
Walker LM. The t(6;11)(q27;q23) translocation in acute leuke-
mia: a laboratory and clinical study of 30 cases. Leukemia.
1998;12:788–91.
28. Dreyling MH, Schrader K, Fonatsch C, et al. MLL and CALM
are fused to AF10 in morphologically distinct subsets of acute
leukemia with translocation t(10;11): both rearrangements are
associated with a poor prognosis. Blood. 1998;91:4662–7.
29. Scholl C, Schlenk RF, Eiwen K, Dohner H, Frohlin S, Dohner K.
The prognostic value of MLL-AF9 detection in patients with
t(9;11)(p22;q23)-positive acute myeloid leukemia. Haematolog-
ica. 2005;90:1626–34.
30. Mrozek K, Heinonen K, Lawrence D, et al. Adult patients with de
novo acute myeloid leukemia and t(9;11)(p22;q23) have a
superior outcome to patients with other translocations involving
band 11q23: a Cancer and Leukemia Group B study. Blood.
1997;90:4532–8.
31. Pasqualucci L, Liso A, Martelli PM, et al. Mutated nucleophosmin
detects clonal multilineage involvement in acute myeloid leuke-
mia: impact on WHO classiﬁcation. Blood. 2006;108:4146–55.
32. Choudhary C, Schwable J, Brandts C, et al. AML-associated Flt3
kinase domain mutations show signal translocation differences
compared with Flt3 ITD mutations. Blood. 2005;106:265–73.
33. Bienz M, Ludwig M, Mueller BU, et al. Risk assessment in
patients with acute myeloid leukemia and a normal karyotype.
Clin Cancer Res. 2005;11:1416–24.
34. Suzuki T, Kiyoi H, Ozeki K, et al. Clinical characteristics and
prognostic implications of NPM1 mutations in acute myeloid
leukemia. Blood. 2005;106:2854–61.
35. Ozeki K, Kiyoi H, Hirose Y, et al. Biologic and clinical signiﬁ-
cance of the FLT3 transcript level in acute myeloid leukemia.
Blood. 2004;103:1901–8.
WHO classiﬁcation of de novo AML 151
123